A Discussion of the Possible Significance of PGI2 in Thrombosis
Before discussing the significance of PGI2 in thrombosis, it is appropriate to acknowledge that its discovery is due to the contributions of three groups. First, credit should be given to Pace-Asciak and Wolfe (1) who in 1971 were working together at McGill University in Montreal. They isolated, identified, and described the unique chemical properties of a noval compound, 6(9)-oxyprostaglandin F2α, which was produced from arachidonic acid by homogenates of rat stomach. Secondly, we would not even be discussing PGI2 today were it not for the discoveries of Moncada, Gryglewski, Vane and others (2,3,4) at the Wellcome Research Laboratories in England. They showed that blood vessels make a prostaglandin, temporarily named PGX, with unique and potent biological properties. Finally, credit is due to Johnson, Morton, and others of The Upjohn Company (5) who collaborated with the Wellcome group and proved that the names 6(9)-oxyprostaglandin F2α and PGX are synonymous. They suggested the use of the trivial name prostacyclin to describe PGX, and I suspect that PGI2 will continue to be called prostacyclin henceforth.
KeywordsEndothelial Cell Arachidonic Acid Inhibit Platelet Aggregation Washed Platelet Prostaglandin Endoperoxide
Unable to display preview. Download preview PDF.
- 15.Weksler BB, Marcus AJ, Jaffe EA: Synthesis of PGI2 (prostacyclin) by cultured human and bovine endothelial cells. PROC NATL ACAD SCI USA (In Press).Google Scholar
- 16.Harker LA, Joy N, Wall RT, Quadracci L, Striker G: Inhibition of platelet reactivity by endothelial cells (Abstract). THROMB HAEMOSTAS 38: 137, 1977.Google Scholar